

HR 5444

Lower Insulin Costs Now Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Dec 17, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Dec 18, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/5444>

Sponsor

Name: Rep. Underwood, Lauren [D-IL-14]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (6 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Guthrie, Brett [R-KY-2]	R · KY		Dec 17, 2019
Rep. Kelly, Mike [R-PA-16]	R · PA		Dec 17, 2019
Rep. Levin, Andy [D-MI-9]	D · MI		Dec 17, 2019
Rep. Schakowsky, Janice D. [D-IL-9]	D · IL		Dec 17, 2019
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Dec 18, 2019
Rep. Perry, Scott [R-PA-10]	R · PA		Dec 23, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Dec 18, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 HR 1865	Related bill	Dec 20, 2019: Became Public Law No: 116-94.
116 HR 19	Related bill	Dec 19, 2019: Referred to the Subcommittee on Antitrust, Commercial, and Administrative Law.

Lower Insulin Costs Now Act

This bill requires the Food and Drug Administration (FDA) to continue to review applications for certain biological products under an earlier review process, notwithstanding recent FDA guidance. (A 2009 law established a new procedure for approving biological products but allowed certain products in an already approved product class to receive approval under the earlier procedure until March 23, 2020; subsequently, in December 2018, the FDA issued guidance stating that an application filed under the earlier procedure that is not approved by March, 23, 2020, will not be approved.)

The bill requires the FDA to continue reviewing an application filed not later than March 23, 2019, under the earlier procedure, even if it was not approved as of March 23, 2020.

Such an application not approved after October 1, 2022, shall be deemed withdrawn.

Such an approved application shall be deemed a biological product license.

Actions Timeline

- **Dec 18, 2019:** Referred to the Subcommittee on Health.
- **Dec 17, 2019:** Introduced in House
- **Dec 17, 2019:** Referred to the House Committee on Energy and Commerce.